The stock of Novartis AG (ADR) (NYSE:NVS) hit a new 52-week low and has $63.86 target or 6.00% below today’s $67.94 share price. The 9 months bearish chart indicates high risk for the $172.23B company. The 1-year low was reported on Nov, 22 by Barchart.com. If the $63.86 price target is reached, the company will be worth $10.33 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 3.74M shares traded hands or 1.08% up from the average. Novartis AG (ADR) (NYSE:NVS) has declined 8.43% since April 20, 2016 and is downtrending. It has underperformed by 12.99% the S&P500.
Novartis AG (ADR) (NYSE:NVS) Ratings Coverage
Out of 9 analysts covering Novartis Ag (NYSE:NVS), 3 rate it a “Buy”, 2 “Sell”, while 4 “Hold”. This means 33% are positive. Novartis Ag has been the topic of 14 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Citigroup downgraded the shares of NVS in a report on Tuesday, March 29 to “Neutral” rating. As per Friday, April 1, the company rating was downgraded by UBS. On Tuesday, April 5 the stock rating was initiated by Argus Research with “Hold”. Chardan Capital Markets initiated the stock with “Buy” rating in Tuesday, September 20 report. The rating was downgraded by Leerink Swann to “Market Perform” on Wednesday, March 23. The stock has “Buy” rating given by Argus Research on Thursday, November 10. The firm earned “Buy” rating on Monday, October 10 by Chardan Capital Markets. As per Tuesday, April 12, the company rating was downgraded by Morgan Stanley. On Wednesday, October 28 the stock rating was downgraded by Mainfirst to “Underperform”.
According to Zacks Investment Research, “Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.”
NVS Company Profile
Novartis AG, incorporated on March 1, 1996, is a holding company. The Firm specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s divisions include Pharmaceuticals, which researches, develops, makes, distributes and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines; Alcon, which operates through over three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, makes and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.